After a series of screenings, we finally included 166 IBD patients (149 CD, 17 UC) who were treated with infliximab or adalimumab and had available ADA levels during the treatment period to conduct data analysis (Figure 1). This evidence concerns the gene ADA and inflammatory bowel disease.